INDIRECT COSTS IN ECONOMIC-STUDIES - CONFRONTING THE CONFUSION

Citation
Ma. Koopmanschap et Ffh. Rutten, INDIRECT COSTS IN ECONOMIC-STUDIES - CONFRONTING THE CONFUSION, PharmacoEconomics, 4(6), 1993, pp. 446-454
Citations number
NO
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
ISSN journal
11707690
Volume
4
Issue
6
Year of publication
1993
Pages
446 - 454
Database
ISI
SICI code
1170-7690(1993)4:6<446:ICIE-C>2.0.ZU;2-7
Abstract
Indirect costs of disease often constitute a substantial part of estim ated costs or savings in economic evaluations of healthcare programmes . The human capital approach is almost unanimously used for estimating indirect costs, defined as production loss due to disease, although a growing number of authors question its validity. This article discuss es the relevance of indirect cost estimates for health policy and revi ews the current empirical and methodological literature on this issue. It describes several important issues and controversies regarding ind irect costs, such as the consequences of short term absence from work for productivity, reduced productivity without absence from work, the influence of unemployment on production loss, the relation between hea lth effects and indirect costs, and the possible medium term macroecon omic consequences of absence from work and disability. It concludes th at indirect costs are relevant for health policy, provided that the es timates of indirect costs reflect the real changes in production due t o disease, including the production of unpaid labour. Future research should focus on attaining these estimates. Indirect costs in economic evaluations should preferably be presented separately from direct cost s, health effects and other study outcomes.